(Sharecast News) - Drugmaker GSK has agreed to acquire Canadian clinical-stage biopharmaceutical firm 35Pharma for $950m in cash.

GSK said on Wednesday that the acquisition includes 35Pharma's HS235, a potential best-in-class investigational medicine that has completed phase I healthy volunteer clinical trials, with studies to start imminently in pulmonary arterial...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE